Chitosan coated nanostructured lipid carriers for brain delivery of proteins by intranasal administration

Colloids and Surfaces B: Biointerfaces

Volumn 134, Issue , 2015, Pages 304-313

  Gartziandia, Oihane ^a,b   Herran, Enara ^a,b   Pedraz, Jose Luis ^a,b   Carro, Eva ^c,d   Igartua, Manoli ^a,b   Hernandez, Rosa Maria ^a,b  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Biodistribution; Blood brain barrier (BBB); Intranasal administration; Nanostructured lipid carrier (NLC); Neurodegenerative disorders (ND)

Indexed keywords

BIOCOMPATIBILITY; BLOOD; CHITOSAN; NEURODEGENERATIVE DISEASES; NONINVASIVE MEDICAL PROCEDURES; PARTICLE SIZE; PROTEINS; TARGETED DRUG DELIVERY;

BIODISTRIBUTIONS; BLOOD-BRAIN BARRIER; INTRANASAL; NANOSTRUCTURED LIPID CARRIER (NLC); NEURODEGENERATIVE DISORDERS;

CONTROLLED DRUG DELIVERY;

CHITOSAN; LIPID; NANOCOATING; NANOMATERIAL; BIOMATERIAL; DRUG CARRIER; PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BIOCOMPATIBILITY; BLOOD BRAIN BARRIER; BRONCHUS MUCOSA; CELL MEDIATED CYTOTOXICITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG DELIVERY SYSTEM; EPITHELIUM CELL; ERYTHROCYTE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRANASAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PARTICLE SIZE; PHYSICAL PARAMETERS; PRIORITY JOURNAL; PROCESS OPTIMIZATION; TOXICITY TESTING; ZETA POTENTIAL; ANIMAL; BRAIN; C57BL MOUSE; CELL LINE; CHEMISTRY; HEMOLYSIS; METABOLISM;

ADMINISTRATION, INTRANASAL; ANIMALS; BRAIN; CELL LINE; CHITOSAN; COATED MATERIALS, BIOCOMPATIBLE; DRUG CARRIERS; HEMOLYSIS; HUMANS; LIPIDS; MICE; MICE, INBRED C57BL; NANOSTRUCTURES; PROTEINS;

EID: 84937908056     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2015.06.054     Document Type: Article

References (28)

1. Foster E.R. Themes from the special issue on neurodegenerative diseases: what have we learned, and where can we go from here?. Am. J. Occup. Ther. 2014, 68(1):6-8.
2. Wong H.L., Wu X.Y., Bendayan R. Nanotechnological advances for the delivery of CNS therapeutics. Adv. Drug Deliv. Rev. 2012, 64(7):686-700.
3. Tajes M., Ramos-Fernandez E., Weng-Jiang X., Bosch-Morato M., Guivernau B., Eraso-Pichot A., et al. The blood-brain barrier: structure, function and therapeutic approaches to cross it. Mol. Membr. Biol. 2014, 31(5):152-167.
4. Cook A.M., Mieure K.D., Owen R.D., Pesaturo A.B., Hatton J. Intracerebroventricular administration of drugs. Pharmacotherapy 2009, 29(7):832-845.
5. Mathias N.R., Hussain M.A. Non-invasive systemic drug delivery: developability considerations for alternate routes of administration. J. Pharm. Sci. 2010, 99(1):1-20.
6. American Academy of Pediatrics Committee on drugs, alternative routes of drug administration-advantages and disadvantages (subject review). Pediatrics 1997, 100(1):143-152.
7. Djupesland P.G., Messina J.C., Mahmoud R.A. The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview. Ther. Deliv. 2014, 5(6):709-733.
8. Reger M.A., Watson G.S., Frey W.H., Baker L.D., Cholerton B., Keeling M.L., et al. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol. Aging 2006, 27(3):451-458.
9. Begley D.J. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol. Ther. 2004, 104(1):29-45.
10. Graff C.L., Pollack G.M. Nasal drug administration: potential for targeted central nervous system delivery. J. Pharm. Sci. 2005, 94(6):1187-1195.
11. Beloqui A., Solinís M.A., Delgado A., Évora C., del Pozo-Rodríguez A., Rodríguez-Gascón A. Biodistribution of nanostructured lipid carriers (NLCs) after intravenous administration to rats: influence of technological factors. Eur. J. Pharm. Biopharm. 2013, 84(2):309-314.
12. Lim S.B., Banerjee A., Önyüksel H. Improvement of drug safety by the use of lipid-based nanocarriers. J. Control. Release 2012, 163(1):34-45.
13. Gobbi M., Re F., Canovi M., Beeg M., Gregori M., Sesana S., et al. Lipid-based nanoparticles with high binding affinity for amyloid-beta1-42 peptide. Biomaterials 2010, 31(25):6519-6529.
14. Vyas T.K., Shahiwala A., Marathe S., Misra A. Intranasal drug delivery for brain targeting. Curr. Drug Deliv. 2005, 2(2):165-175.
15. Severino P., Souto E.B., Pinho S.C., Santana M.H. Hydrophilic coating of mitotane-loaded lipid nanoparticles: preliminary studies for mucosal adhesion. Pharm. Dev. Technol. 2013, 18(3):577-581.
16. Dodane V., Amin Khan M., Merwin J.R. Effect of chitosan on epithelial permeability and structure. Int. J. Pharm. 1999, 182(1):21-32.
17. Dharmala K., Yoo J.W., Lee C.H. Development of chitosan-SLN microparticles for chemotherapy: in vitro approach through efflux-transporter modulation. J. Control. Release 2008, 131(3):190-197.
18. Kurosaki T., Kitahara T., Fumoto S., Nishida K., Yamamoto K., Nakagawa H., et al. Chondroitin sulfate capsule system for efficient and secure gene delivery. J. Pharm. Pharm. Sci. 2010, 13(3):351-361.
19. Leonardi A., Bucolo C., Romano G.L., Platania C.B.M., Drago F., Puglisi G., et al. Influence of different surfactants on the technological properties and in vivo ocular tolerability of lipid nanoparticles. Int. J. Pharm. 2014, 470(1-2):133-140.
20. Drin G., Cottin S., Blanc E., Rees A.R., Temsamani J. Studies on the internalization mechanism of cationic cell-penetrating peptides. J. Biol. Chem. 2003, 278(33):31192-31201.
21. Braz L., Rodrigues S., Fonte P., Grenha A., Sarmento B. Mechanisms of chemical and enzymatic chitosan biodegradability and its application on drug delivery. Biodegradable Polymers: Processing, Degradation and Applications 2011, 325-364. Nova Publishers, New York, USA.
22. Cano-Cebrian M.J., Zornoza T., Granero L., Polache A. Intestinal absorption enhancement via the paracellular route by fatty acids, chitosans and others: a target for drug delivery. Curr. Drug Deliv. 2005, 2(1):9-22.
23. Doktorovova S., Souto E.B., Silva A.M. Nanotoxicology applied to solid lipid nanoparticles and nanostructured lipid carriers - a systematic review of in vitro data. Eur. J. Pharm. Biopharm. 2014, 87(1):1-18.
24. Gainza G., Pastor M., Aguirre J.J., Villullas S., Pedraz J.L., Hernandez R.M., et al. A novel strategy for the treatment of chronic wounds based on the topical administration of rhEGF-loaded lipid nanoparticles: in vitro bioactivity and in vivo effectiveness in healing-impaired db/db mice. J. Control. Release 2014, 185:51-61.
25. Kumar M., Misra A., Mishra A.K., Mishra P., Pathak K. Mucoadhesive nanoemulsion-based intranasal drug delivery system of olanzapine for brain targeting. J. Drug Target. 2008, 16(10):806-814.
26. Patel S., Chavhan S., Soni H., Babbar A.K., Mathur R., Mishra A.K., et al. Brain targeting of risperidone-loaded solid lipid nanoparticles by intranasal route. J. Drug Target. 2011, 19(6):468-474.
27. Md S., Khan R.A., Mustafa G., Chuttani K., Baboota S., Sahni J.K., et al. Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: Pharmacodynamic, Pharmacokinetic and Scintigraphy study in mice model. Eur. J. Pharm. Sci. 2013, 48(3):393-405.
28. Hanson L.R., Frey W.H. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci. 2008, 9:2202-2209.